Literature DB >> 24054978

The multiple layers of non-genetic regulation of PTEN tumour suppressor activity.

Nádia C Correia1, Ana Gírio1, Inês Antunes1, Leila R Martins1, João T Barata2.   

Abstract

Mutations and deletions of the tumour suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) are frequently involved in the development of cancer. However, PTEN is also tightly controlled by various non-genomic mechanisms. This review focuses on those mechanisms, namely on the epigenetic silencing of PTEN, post-transcriptional regulation by non-coding RNAs and post-translational modification. We summarise their involvement in cancer in general, and place some emphasis on leukaemia, where PTEN genetic lesions are relatively uncommon and, strikingly, high levels of PTEN expression frequently associate with PTEN functional inactivation. Overall, it is apparent that rather than looking strictly for PTEN genetic lesions and PTEN expression status, the key to evaluating the real impact of PTEN as a 'quasi-insufficient' tumour suppressor must rely on the complete understanding of PTEN's 'functional dose', incorporating the multiple layers of PTEN regulation in the cell that are ultimately compromised in a given cancer.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Epigenetic, transcriptional, post-transcriptional and post-translational regulation; Leukaemia; Non-genetic inactivation; PI3K–Akt/PKB pathway; PTEN; Tumour suppressor

Mesh:

Substances:

Year:  2013        PMID: 24054978     DOI: 10.1016/j.ejca.2013.08.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  32 in total

1.  Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.

Authors:  Janel L Kopp; Claire L Dubois; David F Schaeffer; Atefeh Samani; Farnaz Taghizadeh; Robert W Cowan; Andrew D Rhim; Bangyan L Stiles; Mark Valasek; Maike Sander
Journal:  Gastroenterology       Date:  2017-12-19       Impact factor: 22.682

2.  PTEN modulates gene transcription by redistributing genome-wide RNA polymerase II occupancy.

Authors:  Ata Abbas; Roshan Padmanabhan; Todd Romigh; Charis Eng
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

3.  PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

Authors:  Marzia Scortegagna; Eric Lau; Tongwu Zhang; Yongmei Feng; Chris Sereduk; Hongwei Yin; Surya K De; Katrina Meeth; James T Platt; Casey G Langdon; Ruth Halaban; Maurizio Pellecchia; Michael A Davies; Kevin Brown; David F Stern; Marcus Bosenberg; Ze'ev A Ronai
Journal:  Cancer Res       Date:  2015-02-24       Impact factor: 12.701

4.  BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

Authors:  Alessandro Morotti; Cristina Panuzzo; Sabrina Crivellaro; Giovanna Carrà; Carmen Fava; Angelo Guerrasio; Pier Paolo Pandolfi; Giuseppe Saglio
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 5.  The Complex Landscape of PTEN mRNA Regulation.

Authors:  Erin Sellars; Martino Gabra; Leonardo Salmena
Journal:  Cold Spring Harb Perspect Med       Date:  2020-06-01       Impact factor: 5.159

6.  Anti-oncogenic PTEN induces ovarian cancer cell senescence by targeting P21.

Authors:  Xiaoping Ke; Li Li; Jingwei Li; Mengyu Zheng; Ping Liu
Journal:  Cell Biol Int       Date:  2021-10-19       Impact factor: 4.473

7.  PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

Authors:  Roberta Ferraldeschi; Daniel Nava Rodrigues; Ruth Riisnaes; Susana Miranda; Ines Figueiredo; Pasquale Rescigno; Praful Ravi; Carmel Pezaro; Aurelius Omlin; David Lorente; Zafeiris Zafeiriou; Joaquin Mateo; Amelia Altavilla; Spyridon Sideris; Diletta Bianchini; Emily Grist; Khin Thway; Raquel Perez Lopez; Nina Tunariu; Chris Parker; David Dearnaley; Alison Reid; Gerhardt Attard; Johann de Bono
Journal:  Eur Urol       Date:  2014-11-04       Impact factor: 20.096

8.  Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.

Authors:  Hui Zhang; Bin Zhao; Cheng Huang; Xiao-Ming Meng; Er-Bao Bian; Jun Li
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

9.  BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.

Authors:  Cristina Panuzzo; Sabrina Crivellaro; Giovanna Carrà; Angelo Guerrasio; Giuseppe Saglio; Alessandro Morotti
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

Review 10.  PTEN: Multiple Functions in Human Malignant Tumors.

Authors:  Michele Milella; Italia Falcone; Fabiana Conciatori; Ursula Cesta Incani; Anais Del Curatolo; Nicola Inzerilli; Carmen M A Nuzzo; Vanja Vaccaro; Sabrina Vari; Francesco Cognetti; Ludovica Ciuffreda
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.